糖生物学市场规模、份额、成长分析（按产品类型、按应用、按最终用户、按地区）- 产业预测 2025-2032

2023 年全球醣生物学市场规模价值 20 亿美元，预计将从 2024 年的 23 亿美元成长到 2032 年的 69.8 亿美元，预测期（2025-2032 年）的复合年增长率为 14.9%。

生物製药产业正在经历显着成长，这得益于对个人化医疗和标靶治疗的重视，这需要更深入地了解细胞和分子动力学，特别是复杂的聚醣结构。这种需求推动了製药和生物技术公司增加研发投资，并得到了质谱和高通量聚醣分析等分析技术的进步的支持，这些技术促进了聚醣功能的研究。在政府法规的支持下，透过产学合作，我们对聚醣在疾病诊断和治疗中的作用的理解正在不断进步，特别是在癌症、感染疾病和自体免疫疾病方面。然而，聚醣固有的结构复杂性、缺乏训练有素的人力、高成本以及新兴经济体的资源有限等挑战阻碍了醣体学在医疗保健领域的进步和应用。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术分析

糖生物学市场规模（按产品类型和复合年增长率） (2025-2032)

• 市场概览
• 酵素
  • 糖苷酶
  • 神经氨酸酶
  • 糖基转移酶
  • 唾液酸转移酶
  • 其他的
• 装置
  • 质谱仪
  • HPLC
  • MALDI-TOF
  • 阵列系统
  • 其他的
• 碳水化合物
  • 寡糖
  • 多醣
  • 其他碳水化合物
• 套件
  • 聚醣标记试剂套件
  • 聚醣精製套件
  • 聚醣释放套件
  • 其他的
• 试剂
  • 糖蛋白
  • 单醣
  • 寡糖
  • 其他的
• 其他的

糖生物学市场规模（依应用）及复合年增长率（2025-2032）

• 市场概览
• 诊断
• 药物研发
• 肿瘤学
• 免疫学
• 其他用途

糖生物学市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 製药和生物技术公司
• 合约研究组织
• 其他最终用户

糖生物学市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Thermo Fisher Scientific（US）
• New England Biolabs（US）
• Merck KGaA（Germany）
• Promega Corporation（US）
• Waters Corporation（US）
• Takara Bio Inc,（Japan）
• Bio-Techne（US）
• Agilent Technologies（US）
• Sumitomo Bakelite Co. Ltd.（Japan）
• Bruker Corporation（US）
• Shimadzu Corporation（Japan）
• Danaher Corporation（US）
• AMS Bio（UK）
• Ludger Ltd（UK）
• Z Biotech, LLC（US）
• Chemily Glycoscience（US）
• CD BioGlyco（US）
• GlycoDiag（France）
• Kode Biotech Limited（New Zealand）
• Glyxera GmBH（Germany）

结论和建议

Global Glycobiology Market size was valued at USD 2.0 billion in 2023 and is poised to grow from USD 2.3 billion in 2024 to USD 6.98 billion by 2032, growing at a CAGR of 14.9% during the forecast period (2025-2032).

The biopharmaceutical industry is experiencing significant growth driven by an emphasis on personalized medicine and targeted therapies, necessitating deeper insights into cellular and molecular dynamics, particularly complex carbohydrate structures. This demand is propelling increased investment in R&D among pharma and biotech firms, supported by advancements in analytical technologies like mass spectrometry and high-throughput glycan analysis facilitating glycan function research. Collaborative efforts between industry and academic institutions, alongside supportive government regulations, are advancing the understanding of glycans in disease diagnostics and treatment, particularly in cancer, infectious, and autoimmune diseases. However, challenges such as the inherent structural complexity of glycans, a shortage of trained personnel, high costs, and limited resources in developing economies hinder progress and adoption of glycomics in the healthcare sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glycobiology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glycobiology Market Segments Analysis

Global Glycobiology Market is segmented by Product Type, Application, End User and region. Based on Product Type, the market is segmented into Enzymes, Instruments, Carbohydrates, Kits, Reagents and Others. Based on Application, the market is segmented into Diagnostics, Drug Discovery and Development, Oncology, Immunology and Other Applications. Based on End User, the market is segmented into Pharmaceutical and Biotechnology Companies, Contract Research Organizations and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Glycobiology Market

The global glycobiology market is significantly influenced by substantial government investments in glycomics research aimed at improving public health. For example, Australia allocated over $10 billion for scientific research innovation between 2017 and 2018, while Ireland invested $5.6 billion in 2015 to boost research activities and increase its scientific workforce from 25,000 to 40,000. Such financial commitments are crucial as they enhance research capabilities and foster advancements in the field. Consequently, these investments contribute to the steady growth of the glycobiology market, highlighting the importance of governmental support in advancing scientific research and development.

Restraints in the Global Glycobiology Market

One of the primary constraints facing the global glycobiology market is the high cost associated with glycobiology research instruments, particularly high-performance liquid chromatography (HPLC) systems and mass spectrometers. These advanced tools can cost anywhere from hundreds of thousands to millions of dollars, making them prohibitively expensive for smaller research laboratories and emerging biotechnology firms. Furthermore, the specialized reagents required for glycan analysis add to the financial burden, limiting the widespread adoption of glycomics technologies across the industry. This financial barrier hinders innovation and can stymie progress in glycobiology research and development.

Market Trends of the Global Glycobiology Market

The Global Glycobiology market is witnessing significant growth, fueled by the rising demand for personalized medicine. As the precision medicine market in Europe is projected to surge from USD 16.72 billion in 2024 to USD 38.26 billion by 2032, the focus on individualized treatment protocols strengthens the role of glycomics. By harnessing unique glycan profiles, glycobiology facilitates the creation of disease-specific drugs and therapies, thereby enhancing therapeutic outcomes. This trend reflects a broader healthcare shift towards more tailored medical solutions, positioning glycobiology at the forefront of innovative therapeutic advancements and contributing to the overall expansion of the life sciences sector globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technology Analysis

Global Glycobiology Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Enzymes
  • Glycosidases
  • Neuraminidases
  • Glycosyltransferases
  • Sialyltransferases
  • Others
• Instruments
  • Mass Spectrometers
  • HPLC
  • MALDI-TOF
  • Array Systems
  • Others
• Carbohydrates
  • Oligosaccharides
  • Polysaccharides
  • Other Carbohydrates
• Kits
  • Glycan Labeling Kits
  • Glycan Purification Kits
  • Glycan Release Kits
  • Others
• Reagents
  • Glycoproteins
  • Monosaccharides
  • Oligosaccharides
  • Others
• Others

Global Glycobiology Market Size by Application & CAGR (2025-2032)

• Market Overview
• Diagnostics
• Drug Discovery and Development
• Oncology
• Immunology
• Other Applications

Global Glycobiology Market Size by End User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Other End Users

Global Glycobiology Market Size & CAGR (2025-2032)

• North America (Product Type, Application, End User)
  • US
  • Canada
• Europe (Product Type, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Thermo Fisher Scientific (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• New England Biolabs (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promega Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Waters Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio Inc, (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Bakelite Co. Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bruker Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shimadzu Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AMS Bio (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ludger Ltd (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Z Biotech, LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chemily Glycoscience (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CD BioGlyco (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlycoDiag (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kode Biotech Limited (New Zealand)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glyxera GmBH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations